Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20590862 | 0.82 | JMJD6 (0.44) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL16799946 | 0.79 | AKR1B1 (0.42) | MAPTCYP2C19ALDH1A1KMT2A | |
| SCHEMBL29650200 | 0.79 | HTR6 (0.43) | MAPTALDH1A1CA2 | |
| SCHEMBL19692897 | 0.79 | HTR6 (0.43) | MAPTALDH1A1CA2 | |
| SCHEMBL35184 | 0.78 | CYP2C19 (0.55) | AKR1C3MAPTIL1RNCYP2C19ALDH1A1 | |
| SCHEMBL29453097 | 0.78 | CYP2C19 (0.55) | AKR1C3MAPTIL1RNCYP2C19ALDH1A1 | |
| SCHEMBL1710551 | 0.77 | ALDH1A1 (0.45) | ALDH1A1LMNACA1CA2MEN1 | |
| SCHEMBL4416606 | 0.77 | ALDH1A1 (0.56) | AKR1C3MAPTIL1RNCYP2C19ALDH1A1 | |
| SCHEMBL29245371 | 0.77 | F2 (0.57) | AKR1C3MAPTIL1RNCYP2C19ALDH1A1 | |
| SCHEMBL19071740 | 0.77 | CYP2C19 (0.54) | AKR1C3MAPTIL1RNCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AKR1C3 269/4885MAPT 2039/4885IL1RN 69/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AKR1C3 212/4885MAPT 2117/4885IL1RN 86/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AKR1C3 269/4885MAPT 2039/4885IL1RN 69/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AKR1C3 269/4885MAPT 2039/4885IL1RN 69/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | AKR1C3 212/4885MAPT 2117/4885IL1RN 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.